OmniAb, Inc.
OmniAb, Inc.
Your view on OABI
Overview
What the company does, where it operates, and who runs it.
About OmniAb, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Matthew W. Foehr
- Headquarters
- US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Matthew W. Foehr
- Headquarters
- US
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics.
Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.
The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for OmniAb, Inc. from FRC's valuation model, read against the market price. OABI last traded at $5.10; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for OmniAb, Inc.. Starting points for OmniAb, Inc.: EPS -$0.34, beta 1.05 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for OmniAb, Inc.. OmniAb, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for OmniAb, Inc.. Trailing twelve-month EPS for OmniAb, Inc. stands at -$0.34. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$4.00
Median
$4.00
High
$4.00
Average target
Analyst Ratings
- Strong Buy0
- Buy11
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.10 | -$0.10 | -$0.31 | -$0.22 |
| Low estimate | -$0.11 | -$0.12 | -$0.34 | -$0.24 |
| High estimate | -$0.08 | -$0.07 | -$0.28 | -$0.20 |
| No. of analysts | 3 | 2 | 4 | 4 |
| Year-ago EPS | -$0.11 | -$0.06 | -$0.57 | — |
| Growth | +11.5% | -58.3% | +46.4% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $5.20M | $7.38M | $36.93M | $46.99M |
| Low estimate | $4.78M | $5.03M | $36.46M | $42.68M |
| High estimate | $5.64M | $9.73M | $37.36M | $51.03M |
| No. of analysts | 5 | 2 | 5 | 5 |
| Year-ago revenue | $8.38M | $14.40M | $18.67M | — |
| Growth | -37.9% | -48.8% | +97.8% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for OmniAb, Inc.. OmniAb, Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
OmniAb, Inc. valued side by side against its closest peers. OmniAb, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
Which funds and firms own the stock.
Which institutions hold OmniAb, Inc., and how their positions are changing. At a $743.9M market value, institutional positions materially move OmniAb, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by OmniAb, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for OmniAb, Inc.. Coverage tracks OmniAb, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of OmniAb, Inc.